Fresenius Medical Price Target Raised to EUR 50 by Deutsche Bank

Deutsche Bank has raised its price target on Fresenius Medical (FMS) to EUR 50 from EUR 45 and maintains a Hold rating on the shares.

Deutsche Bank has revised its price target for Fresenius Medical (FMS) to EUR 50 from EUR 45, while maintaining a Hold rating on the shares [1]. The update comes amidst a period of market volatility and shifting analyst opinions on the healthcare sector.

Fresenius Medical Care AG, a leading provider of dialysis services, has seen its stock price fluctuate around its 200-day moving average. As of July 2, 2025, the stock traded at EUR 46.26, having recently surpassed its 200-day moving average of EUR 46.28 [2]. This recent performance suggests a positive trend, though it remains to be seen whether the stock can sustain this momentum.

Analysts have noted that Fresenius Medical's debt-to-equity ratio of 82.24 and quick ratio of 0.80 indicate a solid financial position. However, the company's price-to-earnings ratio of 20.86 and PEG ratio of 0.42 suggest a relatively low growth potential compared to its peers [2]. This could be a factor in Deutsche Bank's decision to keep a Hold rating despite the higher price target.

Investors should closely monitor the stock's performance and consider the broader market conditions when making investment decisions. While the revised price target indicates potential for growth, it is essential to weigh this against the company's fundamentals and the overall economic outlook.

References:
[1] https://www.tipranks.com/news/the-fly/fresenius-medical-price-target-raised-to-eur-50-from-eur-45-at-deutsche-bank-thefly
[2] https://www.marketbeat.com/instant-alerts/fresenius-medical-care-etrfme-share-price-passes-above-200-day-moving-average-should-you-sell-2025-07-15/